SecBot SecBot
SECBOTREPLAY Home › Report › MESO

MESO · Mesoblast held its 2026 Annual General Meeting, reporting FY2026…

MESOBLAST LTD · 6-K filed Nov 10, 2026 at 18:32 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Nov 10, 2026 at 18:32 ET

Mesoblast held its 2026 Annual General Meeting, reporting FY2026 Ryoncil net revenue of $115M, completing enrollment in the pivotal Phase 3 CLBP trial, and announcing FDA alignment for a BLA filing for rexlemestrocel-L in LVAD patients. The company appointed an interim COO to prepare for commercial scale-up, while two directors retired and one new director was elected. The filing is a routine AGM update with no new financial data beyond previously reported figures.

  • FY2026 Ryoncil net revenue of $115M, gross profit of $110M excluding amortization
  • Phase 3 CLBP trial fully enrolled with 350 patients; readout expected H2 CY2027
  • FDA alignment obtained for BLA filing of rexlemestrocel-L in LVAD patients with GI bleeding
  • Adult SR-aGvHD registrational trial commenced, targeting 40 US sites; interim analysis expected Q4 CY2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access